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Abstract
Human Papillomavirus is the most frequent sexually transmitted infection. Human Papillomavirus (HPV)
is the primary cause of cervical cancer and its precursor lesions. Two prophylactic vaccines against HPV
infections are available. Mathematical models can be used to compare several vaccine strategies. Con-
sequently, most eective vaccine strategy can be enlightened and selected. Nevertheless, proposed HPV
transmission models in the litterature have become very complex while some input values remain unknown
or badly estimated. Our aim was to assess the variability in the outcome variable that is due to the un-
certainty in estimating the input values. We carried out and calibrated a Susceptible-Infected-Susceptible
model of heterosexual transmission of Human Papillomavirus infections for serotypes 6/11/16/18 which
are covered by the quadrivalent vaccine. Immunity obtained from vaccination was considered. The basic
and vaccinated basic reproduction numbers were expressed. Model prediction sensitivity to parameters
uncertainty has been assessed using the Partial Rank Correlation Coecients. Three scenarios of vac-
cination have been compared considering estimated HPV infection prevalences. Six posterior parameter
sets among one million combination tested best tted epidemiologic data. Sensitivity analysis showed
that the signiciance level of uncertainty was linked to the length of dierent serotype HPV infections in
model predictions. Deterministic modeling of HPV infection transmission allowed us to compare poten-
tial eciency of 3 vaccination scenarios. Additional vaccination of the half of men who enter annually in
the sexually active population led to the same results when compared to an exclusive large vaccination
rate of women (who enter annually in the sexually active population). Sensitivity analysis showed the
importance of clearance rate in the precision of model predictions, therefore eorts have to been made
to focus data collection concerning duration of HPV infections. Furthermore, usefulness of men's vacci-
nation depends on women's vaccination rate.
Keywords: Human Papillomavirus, dynamic model, sensitivity analysis, vaccine.
Introduction
Human Papillomavirus (HPV) is the most frequent sexually transmitted infection. At least 70 per cent
of sexually active men and women acquire HPV infection at some points in their lives [29]. Eighty per
cent of HPV infection cases are cleared in a few months from the body by the immune system without
treatment, the rest 20% infection become persistent. One hundred dierent HPV serotypes have been
identied, there are low risk serotypes which are responsible for benign anogenital lesions, and high risk
serotypes which can induce precancerous and cancerous lesions in the cervix. Serotype 16 is the most
common in developed countries [4, 25]. Epidemiological studies on HPV infections establish the role of
these viruses as the primary cause of cervical cancer [22]. These infections are also the cause of anogenital
cancers, head and neck cancers, anogenital warts and recurrent respiratory papillomatosis among women
and men. Invasive cervical cancer is the most common cancer among women worlwide [26]. It is estimated
that HPV infections are responsible for approximately 500,000 cervical cancer cases worldwide each year
[24]. Vaccination against HPV infections represents an eective way to decrease cervical cancer incidence,
1
particularly among young women. Two prophylactic vaccines against HPV infections have been found to
be highly ecient in "naive" women [8].
HPV transmission models have become very complex. Several deterministic models have been developed
to assess the potential impact of vaccination against HPV; Hughes et al [15] developped a SIR model
of heterosexual transmission which included 3 sexual activity groups, their objective was to explore the
eect of a mono-valent high-risk HPV vaccine on the steady-state endemic prevalence of HPV 16 in
the population; Barnabas et al [2] explored the eect of a multivalent HPV vaccine using a SIR model
which included sexual behaviour, smoking and age; Elbasha et al [11] simulated the progression of HPV
disease in the population using 9 compartments, the used SIR model included 2 groups of serotype,
sexual behaviour and 17 age-groups. Taira et al [30] assessed HPV vaccination programs using a SIS
model regarding one serotype stratied by age and sexual activity.
Models cited above were based on numerical simulations with few analytical results. The variability
of model predictions due to the uncertainty in estimating the input values was rarely explored. While
some input parameters are usually unknown and are estimated in the calibration of the model, other
parameters are assessed using epidemiological data. Uncertainty analysis may be used to investigate the
prediction imprecision in the outcome variable that is due to the uncertainty in estimating the values of
the input parameters [16].
In another paper, Elbasha computed the basic and vaccinated reproduction number of a simple SIR
model regarding one HPV-serotype transmission [9]. The basic reproduction number R0 is a threshold
quantity which determines if an epidemic can spread in a population or die out. It is dened by the
expected number of secondary cases of HPV produced by an infected individual during its entire period
of infectiousness, in a completely susceptible population [7].
SIR models are used assuming that individuals who clear HPV infections become immune to a new HPV
infection. While ecient protective immunity against HPV following a rst infection remains uncertain
[17], SIS models may be employed. In this paper, we present a Susceptible-Infected-Susceptible (SIS)
deterministic model of heterosexual transmission of HPV.
We developped and parametrized a two-sex model of HPV infection transmission in a sexually active
population. We included the four serotypes of HPV which are covered by the quadrivalent vaccine. The
basic and vaccinated reproduction numbers are given for the model considering the four HPV serotypes.
We assessed the sensitivity of model predictions to parameter uncertainty. We estimated the potential
impact of a quadrivalent HPV-vaccine on the occurrence of HPV infections comparing 3 vaccination
scenarios.
Method
HPV model structure
The model with vaccination
The model describes HPV infection transmission in a heterosexually active population. We develop a
deterministic model using a Susceptible-Infected-Susceptible (SIS) structure and considering vaccination.
The model includes 2 classes of HPV genotypes: HPV-16/18 (high-oncogenic risk types) and HPV-6/11
(low-risk types). A possible co-infection 6/11/16/18 was also taken into account (gure 1).
Non-vaccinated (resp. vaccinated) women enter the sexually active population in the susceptible com-
partment X00 (resp. V00 ) at a constant rate [(1- ϕf )Λ] (resp. [ϕfΛ]) and leave all compartments at
rate µ. Non-vaccinated (resp. vaccinated) men enter the sexually active population in the susceptible
compartment Y00 (resp. W00 ) at a constant rate [(1- ϕm)Λ] (resp. [ϕmΛ]) and leave all compartments at
rate µ. Then, women can move into infected compartments (if they have an infected contact with a man)
in non-vaccinated population (resp. vaccinated): X01 for women infected with HPV 6/11(resp. V01),
X10 for women infected with HPV 16/18 (resp. V10) and X11 for women infected with HPV 6/11/16/18
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(resp. V11)(detail in Table 1). In the same way , non-vaccinated and vaccinated men can move to infected
compartments. We assume that vaccinated people can be infected. The degree of vaccine protection is
τ , the relative risk of a vaccinated individual experiencing a breakthrough infection is (1-τ). We assume
that vaccinated and infected individuals can transmit HPV as much as non-vaccinated individuals. We
assume that vaccine immunity does not decrease during their sexually active life. Women and men who
clear HPV infection leave infected compartments and go back to the susceptible compartments or infected
compartments with other serotype. Variables and parameters are described in Table 1.
Demographic and biological parameters are strictly positive.
The ordinary dierential equations that represent this compartmental model are presented in Appendix.
Basic and Vaccinated Reproduction Number
In the abscence of vaccination, ϕm = 0 and ϕf = 0 as well as V00 = V01 = V10 = V11 = W00 = W01 =
W10 = W11 = 0. The system of dierential ordinary equations is as follows:
dX00
dt
= Λ−
σf
Nm
(Y01 + Y10 + Y11)X00 + δ01X01 + δ10X10 + δ11X11 − µX00
dX01
dt
=
σf
Nm
Y01X00 −
σf
Nm
(Y11 + Y10)X01 − δ01X01 + δ10X11 − µX01
dX10
dt
=
σf
Nm
Y10X00 −
σf
Nm
(Y11 + Y01)X10 − δ10X10 + δ01X11 − µX10
dX11
dt
=
σf
Nm
Y11X00 +
σf
Nm
(Y11 + Y01)X10 +
σf
Nm
(Y11 + Y10)X01 − (δ10 + δ01 + δ11 + µ)X11 (1)
dY00
dt
= Λ−
σm
Nf
(X01 +X10 +X11)Y00 + δ01Y01 + δ10Y10 + δ11Y11 − µY00
dY01
dt
=
σm
Nf
X01Y00 −
σm
Nf
(X11 +X10)Y01 − δ01Y01 + δ10Y11 − µY01
dY10
dt
=
σm
Nf
X10Y00 −
σm
Nf
(X11 +X01)Y10 − δ10Y10 + δ01Y11 − µY10
dY11
dt
=
σm
Nf
X11Y00 +
σm
Nf
(X11 +X01)Y10 +
σm
Nf
(X11 +X10)Y01 − (δ10 + δ01 + δ11 + µ)Y11
The disease free equilibrium (DFE) of this model is obtained by setting the right hand sides of the model
equations to zero. P0= (X
∗
00, X
∗
01,X
∗
10,X
∗
11, Y
∗
00, Y
∗
01,Y
∗
10,Y
∗
11)= (
Λ
µ
, 0,0,0 ,
Λ
µ
, 0,0,0) is the DFE.
The basic reproduction number R0 is a threshold quantity which determines if an epidemic can spread in
a population or die out. It is dened by the expected number of secondary cases of HPV produced by an
infected individual during its entire period of infectiousness, in a completely susceptible population [7].
We use the Next Generation Matrix (NGM) [32] to compute R0.
R0 is equal to the spectral radius of F1V
−1
1
[6], thus: R0 =
√
R0,fR0,m
with: R0,f =
σf
(min(δ01, δ10) + µ)
and R0,m =
σm
(min(δ01, δ10) + µ)
.
Note that R0 is the geometric mean of two values. In a one-sex model: R0,f = R0,m, we nd
R0 =
σ
(min(δ01, δ10) + µ)
.
Then, considering the system including vaccination compartments (2) (see Appendix), we compute the
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vaccinated reproduction number. The disease free equilibrium (DFE) of this model is:
Q0 = (X
∗∗
00 , X
∗∗
01 , X
∗∗
10 , X
∗∗
11 , Y
∗∗
00 , Y
∗∗
01 , Y
∗∗
10 , Y
∗∗
11 , V
∗∗
00 , V
∗∗
01 , V
∗∗
10 , V
∗∗
11 ,W
∗∗
00 ,W
∗∗
01 ,W
∗∗
10 ,W
∗∗
11 )
=
(
(1− ϕf )
Λ
µ
, 0, 0, 0, (1− ϕm)
Λ
µ
, 0, 0, 0, ϕf
Λ
µ
, 0, 0, 0, ϕm
Λ
µ
, 0, 0, 0
)
The vaccinated reproduction number takes into account vaccine protection. Following the same method
used for the basic reproduction number computation (Next Generation Matrix),
Rv =
1
(min(δ01, δ10) + µ)
√
RmRf
with Rk = σk[(1− ϕk) + (1 − τ)ϕk], for k=f,m.
Also:
R2v = R0
√
[(1− ϕm) + (1− τ)ϕm][(1− ϕf ) + (1 − τ)ϕf ].
Note that terms inside brackets are less than one, Rv < R0. The term under the square root shows
how much vaccination reduces R0. This parameter is very important because it represents a threshold
quantity and bringing it below one could allow the eradication of endemicity of HPV. The level of
impact that is necessary to achieve epidemic elimination depends on the combined eects of male and
female vaccination programs. Considering the basic reproduction number previously obtained, we plot
the critical level of male vaccine coverage that is necessary to achieve epidemic elimination according to
female vaccination rate (gure 2). The impact of female-only vaccination has to be more than 74% to
achieve HPV elimination.
Model simulations
First, we program the system without vaccination in Scilab software. We solve it using a Runge-Kutta
method. Input parameters were evaluated using published data. The rate of exit of the sexually active
population can be estimated as the opposite of the duration of sexually active life [14]. Hughes et al [15]
have estimated the average duration of sexually active life to 15 years. Assuming that the size of the
population in the model is constant, the number of new recruits into the sexually active population (per
year) was estimated to be 30,000. We performed a review of litterature to nd published epidemiological
data on HPV prevalences and average duration of HPV infections for the 4 serotypes 6/11/16/18 in each
gender. We used available epidemiological data regarding general population. US data were used to
estimate prevalences of HPV infection [23, 27]. The annual clearance rate is estimated as the opposite
of the average duration of the infection (in years) [14]. We assumed that clearance rates were similar in
male and female and according to vaccine status. However, clearance rates varied according to serotypes.
Clearance rates in presence of multiple infections were dened as the clearance rate corresponding to
the longest infections. The mean durations of HPV infection estimated in the litterature were dier-
ent according to the explored population. Therefore, type-specic clearance rates were assigned using a
prior uniform distribution between the minimum and maximum estimates found in the litterature review
[11, 13, 15, 19, 20, 21, 28, 31].
Two annual infection rates were dened in male and female and were similar for all serotypes. The infec-
tion rate was the same for a susceptible individual or for someone already infected with other serotypes.
Published estimations of infection rates could not be employed as they depended on the caracteristics of
models used. Consequently, these parameters were generated from a uniform distribution on [0,5]. See
Table 2.
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A tting procedure was performed to identify dierent sets of infection rate. Infection rates were
judged to produce acceptable t when the associated model prediction fell simultaneously within pre-
specied targets dened using the epidemiological data of prevalence. The outputs of the model reached
the target if they were inside intervals of ± 10% of inputs. Inputs were the size of the 8 model com-
partments. Among the million randomly sampled combinations of parameters, 6 sets of natural history
parameters met our predined goodness-of-t criteria. Model simulations were based on one posterior
parameter set that was identied during model tting.
Sensitivity analysis
An uncertainty analysis was performed. First, we studied the impact of a 20% parameter variation on
model predictions. We considered variations of new recruit and retirment rate of the sexually active
population together, then variations of clearance rates and infection rates together, nally variations of
initial prevalences. Each time, the predictions of the model were compared to the pre-specied target.
Then, in sensitivity analysis, we identied the most inuential parameters on model predictions computing
Partial Rank Correlation Coecient (PRCC)[5]. Calculation of PRCC enables the determination of the
statistical relationships between each input parameter and each outcome variable while keeping all of
the other input parameters constant. The magnitude of the PRCC indicates the importance of the
uncertainty in estimating the value of the outcome variable. However, in this analysis we only kept
outcome variables which were monotonically related to the input parameters. In this analysis, we used
R sofware (www.r-project.org).
Vaccine characteristics
Base-case vaccine characteristics were assumed to be as follows: reduction in susceptibility to HPV
6/11/16/18 (vaccine ecacy) was 90%, vaccine duration is lifelong, vaccinated people which are infected
are as infectious as the non-vaccinated infected people. We compared 3 scenarios of vaccination (Table
2) considering a signicant reduction of HPV-16/18 infected men and women. We calculated how many
years were necessary after introduction of vaccination to have the size of HPV-16/18 infected compart-
ments below 10,000.
Results
Model t and validation
Of one million dierent combinations of parameters sampled from the uniform distributions, 6 parameter
sets produced model results within the prespecied targets (Table 3).
These 6 combinations were dierent. In each of the 6 combinations, a 10% variation of one parameter while
keeping the others constant did not produced output in the pre-dened target. The third combination
was used in the analyses that follow. We could assess a R0 value at 1.73. As expected, this value was
above 1 because HPV infections have reached an endemic state. This value did not give an estimation for
the time which was necessary to eradicate HPV infections. In the section for vaccine scenario, we estimate
how many years are needed in order to observe a signicant diminution of HPV infected individuals.
Sensitivity analysis
In a rst step, we assessed the eect of parameter variations in a scale of 20% (increase or decrease) on
the predictions of the model. When considering prevalence parameters, predictions of the model achieved
the pre-specied target. Nonetheless, modication regarding the rates of entrance and withdrawal from
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sexually active population inuenced in a moderate way model predictions. On the contrary, clearance
and infection rate variations led to predictions outside the target.
In a second step, we conducted a sensitivity analysis using PRCC. Monotonicity between each input
variables and output variables was assessed considering scatterplots. Only outcome variables which were
monotically related to the input parameters were used to compare the PRCC. We computed PRCC
between each 4 input parameters (female infection rate, men infection rate, HPV-6/11 clearance rate and
HPV-16/18 infection rate) and the 8 output variables (size of the 8 non-vaccinated compartments). The
relative importance of the input variables could be directly evaluated by comparing these PRCC (Table
4).
Considering signicant results of PRCC, it can be found that the uncertainties in estimating the values of
clearance rate for HPV 6/11 and HPV 16/18 are the most important in aecting the prediction precision of
susceptible population. Female infection rate estimation uncertainties contribute to prediction precision
of HPV-6/11 infected men and women. In this case, PRCC relating to men are smaller that PRCC
relating to women but it can been explain by the non-monotonous relation for men infection rate with
all output variables. In this case, it could implicate that the PRCC is low.
Vaccine scenarios
In the case of a low vaccine coverage for women (50% of women who enter annually the sexually active
population) and without men's vaccination (scenario 1), 50 years were necessary, after vaccine introduc-
tion, to observe less than 10,000 HPV-16/18 infected women (gure 3). Introduction of men's vaccine
in scenario 2 reduced by half this time. The third scenario was caracterised by a high vaccine coverage
among women (90% of women who enter, annually, the sexually active population) and the absence of
men's vaccination. In this case, we found the same time again that with the second scenario in which
half of men and women, who enter annually the sexually active population, were vaccinated.
Discussion
Two prophylactic vaccines against HPV infections are proposed to young women in several countries.
In the United States, the Centers for Disease Control and Prevention (CDC) recommend vaccination
for girls and women 11 to 26 years old with quadrivalent vaccine, in order to prevent cervical cancer,
pre-cancerous lesions and genital warts caused by serotypes 6, 11, 16 and 18. In Europe, several coun-
tries recommend vaccination against HPV infection, vaccination against HPV starts at dierent ages,
between 9 and 14 years [1]. Actually, the question of vaccination for boys is being studied [3, 12, 18, 10].
Mathematical models are useful to appreciate the impact of prophylactic vaccination against HPV and
the eectiveness of vaccination strategies, for instance introduction of boy's vaccination. Previously, no
SIS model including the four HPV serotypes covered by the quadrivalent vaccine have been developped.
Only Taira et al [30] have published a SIS model including only one serotype of HPV. In this paper, we
developped a deterministic SIS model of heterosexually HPV transmission including the four serotypes
covered by the quadrivalent vaccine. We derived explicit formula for the basic and vaccinated reproduc-
tion numbers that characterizes whether the epidemic will be contained following vaccination or not. We
found that the basic reproduction number is
R0 =
√
σf
(min(δ01, δ10) + µ)
σm
(min(δ01, δ10) + µ)
and the vaccinated reproduction number was assessed:
Rv = R0
√
[(1 − ϕm) + (1− τ)ϕm][(1 − ϕf ) + (1− τ)ϕf ]
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Then we have estimated the infection and clearance rates in calibration step. As expected, female infection
rates were above male infection rates because the transmission risk from an infected man to a susceptible
woman is higher than from an infected woman to a susceptible man [2, 11, 15]. The estimated infection
rates were hardly comparable with those found in the litterature because most of the published models are
stratied on sexual behavior and age [2, 11, 15]. Parameters assessed in these models are the probability
of transmission. Sexual behavior is introduced using average rate of sexual partner change and a mixing
matrice which describes how partnerships between men and women are formed. The clearance rates
(Table 2) were near to the lower values found in the litterature. They corresponded to longer durations
of infection. Furthermore, sensitivity analysis showed that clearance rates have an important impact on
model predictions. In published studies, infected women are seen every 6 months to assess the average
duration of HPV infection, this period implicates an uncertainty with respect to the exact time of HPV
clearance [28, 31, 33]. Thus, more accurate epidemiological data on the duration of HPV infections could
improve the precision of model predictions.
Introduction of vaccination in the model allowed us to compare 3 scenarios for vaccination. In the
rst scenario, we considered that 50% of women who enter annually in the sexually active population
were vaccinated. Since vaccine recommandations in US are vaccination at 12 years old (and a catch-up
programm for 13-26 years old girls) this scenario corresponded to half of the 14 years old girls, who
enter annually in the model protected by the vaccine. Introduction of men's vaccination besides women's
vaccination (scenario 2 vs scenario 1) allows to obtain a twice as fast diminution of HPV-16/18 infected
individual number. Nevertheless, we found the same fastness with an exclusive high female vaccine
coverage (90%) (scenario 3). Therefore, men's vaccination eectiveness has to be discussed according
to vaccine coverage acquired for women. These results come from a simplied model and have to be
conrmed by developing a model including age and sexual behaviour.
Acknowledgments
The authors would like to thank Hector de Arazoza, Kamel Senouci, Adrien Dozol and Bilal Majed for
their invaluable help.
References
[1] European Cervical Cancer Association. Hpv vaccination across europe. report,
http://www.ecca.info/fr/ecca-publications.html.
[2] Ruanne V Barnabas, Päivi Laukkanen, Pentti Koskela, Osmo Kontula, Matti Lehtinen, and Ge-
o P Garnett. Epidemiology of hpv 16 and cervical cancer in nland and the potential impact of
vaccination: mathematical modelling analyses. PLoS Med, 3(5):e138, May 2006.
[3] Philip E Castle and Isabel Scarinci. Should hpv vaccine be given to men? BMJ, 339:b4127, 2009.
[4] G. M. Cliord, J. S. Smith, M. Plummer, N. Muñoz, and S. Franceschi. Human papillomavirus types
in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer, 88(1):6373, Jan 2003.
[5] WJ Conover. Practical Nonparametric statistics. John Wiley and Sons New York, 1980.
[6] O. Diekmann, J. A. Heesterbeek, and J. A. Metz. On the denition and the computation of the
basic reproduction ratio r0 in models for infectious diseases in heterogeneous populations. J Math
Biol, 28(4):365382, 1990.
[7] O. Diekmann, J. A P Heesterbeek, and M. G. Roberts. The construction of next-generation matrices
for compartmental epidemic models. J R Soc Interface, 7(47):873885, Jun 2010.
7
[8] Joakim Dillner, Susanne K Kjaer, Cosette M Wheeler, Kristján Sigurdsson, Ole-Erik Iversen, Mauri-
cio Hernandez-Avila, Gonzalo Perez, Darron R Brown, Laura A Koutsky, Eng Hseon Tay, Patricia
García, Kevin A Ault, Suzanne M Garland, Sepp Leodolter, Sven-Eric Olsson, Grace W K Tang,
Daron G Ferris, Jorma Paavonen, Matti Lehtinen, Marc Steben, F. Xavier Bosch, Elmar A Joura,
Slawomir Majewski, Nubia Muñoz, Evan R Myers, Luisa L Villa, Frank J Taddeo, Christine Roberts,
Amha Tadesse, Janine T Bryan, Roger Maansson, Shuang Lu, Scott Vuocolo, Teresa M Hesley, Eliav
Barr, and Richard Haupt. Four year ecacy of prophylactic human papillomavirus quadrivalent vac-
cine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts:
randomised controlled trial. BMJ, 341:c3493, 2010.
[9] Elamin E Elbasha. Impact of a prophylactic vaccination against human papillomavirus infection.
Contemporary Math., 410, 2006.
[10] Elamin H Elbasha and Erik J Dasbach. Impact of vaccinating boys and men against hpv in the
united states. Vaccine, 28(42):68586867, Oct 2010.
[11] Elamin H Elbasha, Erik J Dasbach, and Ralph P Insinga. Model for assessing human papillomavirus
vaccination strategies. Emerg Infect Dis, 13(1):2841, Jan 2007.
[12] Carlo Foresta, Alberto Ferlin, and Andrea Garolla. Hpv vaccination. what about male specic hpv
related diseases? BMJ, 339:b4514, 2009.
[13] E. L. Franco, L. L. Villa, J. P. Sobrinho, J. M. Prado, M. C. Rousseau, M. Désy, and T. E. Rohan.
Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from
a high-risk area for cervical cancer. J Infect Dis, 180(5):14151423, Nov 1999.
[14] H Hethcote. Qualitative analyses of communicable disease models. Mathematical Biosciences, 1976.
[15] James P Hughes, Geo P Garnett, and Laura Koutsky. The theoretical population-level impact of
a prophylactic human papilloma virus vaccine. Epidemiology, 13(6):631639, Nov 2002.
[16] RL Iman. An investigation of uncertainty and sensitivity analysis techniques for computer models.
Risk Analysis, 8:71:90, 1988.
[17] Ralph P Insinga, Erik J Dasbach, and Elamin H Elbasha. Epidemiologic natural history and clinical
management of human papillomavirus (hpv) disease: a critical and systematic review of the literature
in the development of an hpv dynamic transmission model. BMC Infect Dis, 9:119, 2009.
[18] Jane J Kim and Sue J Goldie. Cost eectiveness analysis of including boys in a human papillomavirus
vaccination programme in the united states. BMJ, 339:b3884, 2009.
[19] Jill Koshiol, Jane Schroeder, Denise J Jamieson, Stephen W Marshall, Ann Duerr, Charles M Heilig,
Keerti V Shah, Robert S Klein, Susan Cu-Uvin, Paula Schuman, David Celentano, and Jennifer S
Smith. Smoking and time to clearance of human papillomavirus infection in hiv-seropositive and
hiv-seronegative women. Am J Epidemiol, 164(2):176183, Jul 2006.
[20] Satu-Maria A Kulmala, Irena P Shabalova, Nikolay Petrovitchev, Kari J Syrjänen, Ulf B Gyllensten,
Bo C Johansson, Stina M Syrjänen, and New Independent States of the former Soviet Union Cohort
Study Group. Type-specic persistence of high-risk human papillomavirus infections in the new
independent states of the former soviet union cohort study. Cancer Epidemiol Biomarkers Prev,
16(1):1722, Jan 2007.
[21] Anna-Barbara Moscicki, Jonas H Ellenberg, Sepideh Farhat, and Jiahong Xu. Persistence of human
papillomavirus infection in hiv-infected and -uninfected adolescent girls: risk factors and dierences,
by phylogenetic type. J Infect Dis, 190(1):3745, Jul 2004.
8
[22] N. Muñoz. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol, 19(1-2):1
5, Oct 2000.
[23] C. M. Nielson. Type-specic prevalence and persistence of human papillomavirus in women in the
united states who are referred for typing as a component of cervical cancer screening. Am J Obstet
Gynecol, 200(3):245, 2009.
[24] S Pagliosi. Human papillomavirus and cervical cancer. Technical report, World Health Organization.
[25] C. Pannier-Stockman, C. Segard, S. Bennamar, J. Gondry, J-C. Boulanger, H. Sevestre, S. Castelain,
and G. Duverlie. Prevalence of hpv genotypes determined by pcr and dna sequencing in cervical
specimens from french women with or without abnormalities. J Clin Virol, 42(4):353360, Aug 2008.
[26] D. M. Parkin, P. Pisani, and J. Ferlay. Estimates of the worldwide incidence of 25 major cancers in
1990. Int J Cancer, 80(6):827841, Mar 1999.
[27] H.E. Ralston, Z. Li, RC McGlennen, WL Hellerstedt, and LS Downs Jr. Type-specic prevalence
and persistence of human papillomavirus in women in the united states who are referred for typing as
a component of cervical cancer screening. American journal of obstetrics and gynecology, 200(3):245,
2009.
[28] Harriet Richardson, Michal Abrahamowicz, Pierre-Paul Tellier, Gail Kelsall, Roxane du Berger, Alex
Ferenczy, François Coutlée, and Eduardo L Franco. Modiable risk factors associated with clearance
of type-specic cervical human papillomavirus infections in a cohort of university students. Cancer
Epidemiol Biomarkers Prev, 14(5):11491156, May 2005.
[29] K Syrjnen, M. Hakama, S. Saarikoski, M. Vyrynen, M. Yliskoski, S. Syrjnen, V. Kataja, and O. Cas-
tren. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections
in a nonselected nnish female population. Sex Transm Dis, 17(1):159, 1990.
[30] Al V Taira, Christopher P Neukermans, and Gillian D Sanders. Evaluating human papillomavirus
vaccination programs. Emerg Infect Dis, 10(11):19151923, Nov 2004.
[31] Helen Trottier, Salaheddin Mahmud, José Carlos M Prado, Joao S Sobrinho, Maria C Costa,
Thomas E Rohan, Luisa L Villa, and Eduardo L Franco. Type-specic duration of human pa-
pillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect
Dis, 197(10):14361447, May 2008.
[32] P. Van den Driessche and James Watmough. Reproduction numbers and sub-threshold endemic
equilibria for compartmental models of disease transmission. Math Biosci, 180:2948, 2002.
[33] C. B. Woodman, S. Collins, H. Winter, A. Bailey, J. Ellis, P. Prior, M. Yates, T. P. Rollason,
and L. S. Young. Natural history of cervical human papillomavirus infection in young women: a
longitudinal cohort study. Lancet, 357(9271):18311836, Jun 2001.
9
Appendix
The ordinary dierential equations that represent the compartmental model including vaccination are :
dX00
dt
= (1− ϕf )Λ −
σf
Nm
(Y01 + Y10 + Y11 +W01 +W10 +W11)X00 + δ01X01 + δ10X10 + δ11X11 − µX00
dX01
dt
=
σf
Nm
(Y01 +W01)X00 −
σf
Nm
(Y11 +W11 + Y10 +W10)X01 − δ01X01 + δ10X11 − µX01
dX10
dt
=
σf
Nm
(Y10 +W10)X00 −
σf
Nm
(Y11 +W11 + Y01 +W01)X10 − δ10X10 + δ01X11 − µX10
dX11
dt
=
σf
Nm
(Y11 +W11)X00 +
σf
Nm
(Y11 +W11 + Y01 +W01)X10
+
σf
Nm
(Y11 +W11 + Y10 +W10)X01 − (δ10 + δ01 + δ11 + µ)X11
dY00
dt
= (1− ϕm)Λ −
σm
Nf
(X01 +X10 +X11 + V01 + V10 + V11)Y00 + δ01Y01 + δ10Y10 + δ11Y11 − µY00
dY01
dt
=
σm
Nf
(X01 + V01)Y00 −
σm
Nf
(X11 + V11 +X10 + V10)Y01 − δ01Y01 + δ10Y11 − µY01
dY10
dt
=
σm
Nf
(X10 + V10)Y00 −
σm
Nf
(X11 + V11 +X01 + V01)Y10 − δ10Y10 + δ01Y11 − µY10
dY11
dt
=
σm
Nf
(X11 + V11)Y00 +
σm
Nf
(X11 + V11 +X01 + V01)Y10
+
σm
Nf
(X11 + V11 +X10 + V10)Y01 − (δ10 + δ01 + δ11 + µ)Y11
dV00
dt
= ϕfΛ− (1− τ)
σf
Nm
(Y01 + Y10 + Y11 +W01 +W10 +W11)V00 + δ01V01 + δ10V10 + δ11V11 − µV00 (2)
dV01
dt
= (1− τ)
σf
Nm
(Y01 +W01)V00 − (1− τ)
σf
Nm
(Y11 +W11 + Y10 +W10)V01 − δ01V01 + δ10V11 − µV01
dV10
dt
= (1− τ)
σf
Nm
(Y10 +W10)V00 − (1− τ)
σf
Nm
(Y11 +W11 + Y01 +W01)V10 − δ10V10 + δ01V11 − µV10
dV11
dt
= (1− τ)
σf
Nm
(Y11 +W11)V00 + (1− τ)
σf
Nm
(Y11 +W11 + Y01 +W01)V10
+ (1− τ)
σf
Nm
(Y11 +W11 + Y10 +W10)V01 − (δ10 + δ01 + δ11 + µ)V11
dW00
dt
= ϕmΛ− (1− τ)
σm
Nf
(X01 +X10 +X11 + V01 + V10 + V11)W00 + δ01W01 + δ10W10 + δ11W11 − µW00
dW01
dt
= (1− τ)
σm
Nf
(X01 + V01)W00 − (1 − τ)
σm
Nf
(X11 + V11 +X10 + V10)W01 − δ01W01 + δ10W11 − µW01
dW10
dt
= (1− τ)
σm
Nf
(X10 + V10)W00 − (1 − τ)
σm
Nf
(X11 + V11 +X01 + V01)W10 − δ10W10 + δ01W11 − µW10
dW11
dt
= (1− τ)
σm
Nf
(X11 + V11)W00 + (1 − τ)
σm
Nf
(X11 + V11 +X01 + V01)W10
+ (1− τ)
σm
Nf
(X11 + V11 +X10 + V10)W01 − (δ10 + δ01 + δ11 + µ)W11
10
with
Nf = X00 +X01 +X10 +X11 ++V00 + V01 + V10 + V11
Nm = Y00 + Y01 + Y10 + Y11 ++W00 +W01 +W10 +W11
N = Nf +Nm.
N is the size of the sexually active population. We have
N ′ = 2Λ− µN.
Since at equilibrium N∗ = 2Λ
µ
.
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Figure 1. Transfer diagram of the HPV model. The dierent compartments represent individuals
in each state of HPV infection (rounded up corner for vaccinated population, S: non- vaccinated and
susceptible, V: vaccinated and susceptible, I 6/11: infected with HPV-6 or/and HPV-11, I 16/18:
infected with HPV-16 or/and HPV-18, I 6/11/16/18: infected with HPV-6 or/and HPV-11 and HPV-16
or/and HPV-18). The arrows represent the ow between these states (bold lines represent entrance into
the sexually-active population, solid lines represent infection, dashed lines represent clearance and
regression, dotted lines represent the exit of the model).
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Figure 2. Gender-specic vaccine impact necessary to achieve epidemic elimination when
R20 = 2.99.
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Figure 3. Prevalences of HPV-16/18 infected women considering 3 scenarios of
vaccination. At t=0 introduction of vaccine, stars represent the scenario 1, solid line represents the
scenario 2, dashed line represents the scenario 3.
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Table 1. Description of variables and parameters
Symbol Description
Variables
Non-vaccinated (Vaccinated population)
X00(t) (V00(t)) Susceptible women
X01(t) (V01(t)) Infected women with HPV 6/11
X10(t) (V10(t)) Infected women with HPV 16/18
X11(t) (V11(t)) Infected women with HPV 6/11/16/18
Y00(t) (W00(t)) Susceptible men
Y01(t) (W01(t)) Infected men with HPV 6/11
Y10(t) (W10(t)) Infected men with HPV 16/18
Y11(t) (W11(t)) Infected men with HPV 6/11/16/18
Demographic parameters
Λ New recruits into the sexually active population
µ Death or remove rate from the sexually active population
Biological parameters
σf Infection rate for women
σm Infection rate for men
δ01 Clearance rate for HPV 6/11
δ10 Clearance rate for HPV 16/18
δ11 Clearance rate for HPV 6/11/16/18
Vaccines Parameters
ϕf female vaccination rate
ϕm male vaccination rate
τ degree of vaccine protection
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Table 2. Model's parameters
Parameters Values Reference number(s)
Demographic
Size of women population Nf 500,000 *
Size of men population Nm 500,000 *
New recruits into the sexually active population (per year) Λ 30,000 1
2
µN †
Death or remove rate from the sexually active population 6% [15]
(per year) µ
Natural history ‡ Parameter range
Infection rate for women σf 0-5 Assumption
Infection rate for men σm 0-5 Assumption
Clearance rate for HPV 6/11 (δ01), 16/18 (δ10) 0.6-2 [11, 13, 15, 20, 21, 28, 31]
Clearance rate for HPV 6/11/16/18 (δ11) = δ10 longest duration
Vaccines
Degree of vaccine protection τ 90% [8]
Vaccination rate Female Male
Scenario 1 50% 0%
Scenario 2 50% 50%
Scenario 3 90% 0%
∗
compartment size large enough to apply a deterministic model
† assumption to have a constant population size in the model
‡ The natural history parameters are annual transition rates
Table 3. Combinations of parameters which product results within the prespecied target
1 2 3† 4 5 6
Infection rate for women* 1.02 1.14 1.49 1.57 2.36 2.37
Infection rate for men* 0.75 0.68 0.90 0.95 1.75 1.52
Clearance rate HPV-6/11* 0.64 (18.8) 0.65 (18.5) 0.87 (13.8) 0.91 (13.2) 1.55 (7.7) 1.46 (8.2)
Clearance rate HPV-16/18* 0.62 (19.4) 0.63 (19.0) 0.84 (14.3) 0.88 (13.6) 1.5 (8.0) 1.42 (8.4)
*Annual rates
Duration of infection are in parentheses (in months)
† combination used in the sensitivity analyses and the comparison of vaccination scenarios.
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Table 4. Partial rank correlation coecients
Female inf. rate Male inf. rate HPV-6/11 clear. rate HPV-16/18 clear. rate
Size of compartment:
Susceptible women -0.77 -0.44 † 0.66* 0.67*
HPV-6/11 inf. women 0.64* 0.39*† -0.86 0.41*†
HPV-16/18 inf. women 0.57*† 0.36*† 0.47*† -0.85
HPV-6/11/16/18 inf. women 0.4* 0.26*† -0.36† -0.45 †
Susceptible men -0.7 -0.62† 0.66* 0.67*
HPV-6/11 inf. men 0.61* 0.46*† -0.86 0.41*†
HPV-16/18 inf. men 0.53*† 0.44*† 0.46*† -0.85
HPV-6/11/16/18 inf. men 0.4* 0.27*† -0.36† -0.44†
* the results are signicant at the 0.001 level
† non monotonous link between input and output
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